Thu, Jul 24, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Barclay Hedge Fund Index gains 1.32% in April (3.24% YTD), Healthcare & Biotechnology index best performer with +3.45% (6.10% YTD)

Monday, May 16, 2011
Opalesque Industry Update – Hedge funds gained 1.32% in April according to the Barclay Hedge Fund Index compiled by BarclayHedge. Year-to-date the Index is up 3.24%.

“Higher prices for equities and bonds in April provided an accommodating environment for most hedge fund strategies,” says Sol Waksman, founder and president of BarclayHedge.

“Strength in the bond market despite US dollar weakness and a well bid equity market took many participants by surprise,” says Waksman. “Yet looking at the positive returns of fixed income-based strategies in April, it appears that hedge fund managers were not caught unawares.

All but two of Barclay’s 18 hedge fund indices had gains in April. The Barclay Healthcare & Biotechnology Index was up 3.45%, Technology gained 2.67%, Global Macro was up 1.96%, Emerging Markets gained 1.82%, and the European Equities Index rose 1.78%.

“Hedge funds have made steady progress since September of 2010, as evidenced by eight straight months of gains for the Barclay Hedge Fund Index,” says Waksman.

The Equity Short Bias Index has lost ground for eight months in a row and gave up another 1.94% in April. Equity Short Bias is down 7.66% year-to-date.

The Barclay Fund of Funds Index gained 1.14% in April and is up 1.98% in 2011.

(press release)

Performance tables: Source

BarclayHedge was founded in 1985 and actively tracks more than 6,000 hedge funds, funds of hedge funds, and managed futures programs. Each month Barclay provides updated performance rankings for 38 Hedge Fund categories and 16 CTA categories.

Bg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing
  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Events – AIMA Australian Hedge Fund Forum, Sept. 16, Sydney[more]

    AIMA Australia invite you to join us at our annual Hedge Fund Forum on Tuesday 16th September 2014 at the Sofitel Sydney Wentworth. The AIMA Australian Hedge Fund Forum is a non-profit hedge fund conference organised by the industry for the industry, featuring quality Australian and internation

  2. Opalesque Exclusive: Loeb, Grantham cite growing economic concerns in letters[more]

    Bailey McCann, Opalesque New York: Hedge fund manager Daniel Loeb, head of Third Point, and Jeremy Grantham of Grantham, Mayo, Van Otterloo & Co. have both released their quarterly investor letters today. While news is positive on some fronts, and both men see pockets of opportunity, they also h

  3. Investing – Hedge funds expect Netflix earnings to catapult forward, Third Point's Loeb takes stakes in Fibra Uno, YPF, Royal DSM, Lake Capital in talks to back Engine Group[more]

    Hedge funds expect Netflix earnings to catapult forward From Investing.com: Netflix has made major strides forward in 2014 despite ongoing battles with the FCC and cable companies over the issue of net neutrality. The FCC has now received over 500,000 comments from the public on its pend

  4. Opalesque Roundtable: Success in hedge fund marketing not linked to performance, but investor appetite[more]

    Komfie Manalo, Opalesque Asia: Success in marketing a fund is not linked to the performance, but to investor appetite, to the way you can market the fund, and to how much time you can spend to raise assets, said Antoine Rolland, the CEO of incubator and seeding firm

  5. Hedge fund manager Winton Capital making headway with long-only strategy[more]

    From PIonline.com: North American investors are helping Winton Capital Management Ltd. make progress — albeit slowly — toward its founder's goal of becoming a $100 billion company. The firm's ticket to quadrupling its assets under management is unlikely to be one of its scientifically designed manag